Related Experiment Video
Updated: Dec 27, 2025
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
The Heart Failure with Preserved Ejection Fraction Conundrum-Redefining the Problem and Finding Common Ground?
P Iyngkaran1, M C Thomas2, C Neil3
1Werribee Mercy Sub School, School of Medicine, Sydney, Australia.
Insights
Heart failure with preserved ejection fraction (HFpEF) affects over half of congestive heart failure cases. New diagnostic and therapeutic approaches are needed as current treatments for HFpEF lack efficacy data.
Area of Science:
- Cardiology
- Heart Failure Research
Background:
- Heart failure with preserved ejection fraction (HFpEF), also known as diastolic heart failure (DHF), constitutes over 50% of congestive heart failure (CHF) cases.
- The increasing elderly population is projected to drive an epidemic rise in HFpEF, escalating healthcare costs and straining infrastructure.
- Unlike systolic heart failure (SHF), HFpEF presents significant uncertainties regarding risk factors, pathophysiology, and effective treatment monitoring.
Purpose of the Study:
- To review current understanding and recent advancements in the field of HFpEF.
- To highlight the limitations in diagnosing and managing HFpEF compared to SHF.
- To provide perspective on emerging trends and future directions in HFpEF research.
Main Methods:
- Review of recent epidemiological observations and guideline changes.
- Analysis of diagnostic tools, including the role of exercise diastolic stress testing.
- Evaluation of current therapeutic strategies and their limitations in HFpEF.
Main Results:
- Existing guidelines for HFpEF rely heavily on general symptoms and static echocardiographic parameters.
- The exercise diastolic stress test offers a more dynamic assessment and warrants increased clinical focus.
- Current therapeutic options for HFpEF are largely extrapolated from SHF without specific prognostic data.
Conclusions:
- HFpEF represents a growing clinical challenge with evolving diagnostic and therapeutic landscapes.
- Further research is essential to clarify risk factors, pathophysiology, and develop effective, evidence-based treatments for HFpEF.
- The field anticipates significant advancements and new thinking in HFpEF management over the next decade.
Purpose Of Review:
Heart failure with preserved ejection fraction (HFpEF) or diastolic heart failure (DHF) makes up more than half of all congestive heart failure presentations (CHF). With an ageing population, the case load and the financial burden is projected to increase, even to epidemic proportions. CHF hospitalizations add too much of the financial and infrastructure strain. Unlike systolic heart failure (SHF), much is still either uncertain or unknown. Specifically, in epidemiology, the disease burden is established; however, risk factors and pathophysiological associations are less clear; diagnostic tools are based on rigid parameters without the ability to accurately monitor treatments effects and disease progression; finally, therapeutics are similar to SHF but without prognostic data for efficacy.
Recent Findings:
The last several years have seen guidelines changing to account for greater epidemiological observations. Most of these remain general observation of shortness of breath symptom matched to static echocardiographic parameters. The introduction of exercise diastolic stress test has been welcome and warrants greater focus. HFpEF is likely to see new thinking in the coming decades. This review provides some of perspective on this topic.
Related Concept Videos
01:17Pathophysiology of Heart Failure
01:30Heart Failure IV: Classification and Diagnostic Evaluation
01:29Heart Failure II: Pathophysiology
01:27Heart Failure I: Introduction
01:26Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
01:30Heart Failure VII: Nursing Interventions